Salarius Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SLRX and other ETFs, options, and stocks.

About SLRX

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. 

CEO
Frederick E. Pierce
CEOFrederick E. Pierce
Employees
2
Employees2
Headquarters
Houston, Texas
HeadquartersHouston, Texas
Founded
2014
Founded2014
Employees
2
Employees2

SLRX Key Statistics

Market cap
4.08M
Market cap4.08M
Price-Earnings ratio
-0.02
Price-Earnings ratio-0.02
Dividend yield
Dividend yield
Average volume
344.66K
Average volume344.66K
High today
$0.7169
High today$0.7169
Low today
$0.6551
Low today$0.6551
Open price
$0.6725
Open price$0.6725
Volume
225.36K
Volume225.36K
52 Week high
$108.00
52 Week high$108.00
52 Week low
$0.64
52 Week low$0.64

Stock Snapshot

Salarius Pharmaceuticals(SLRX) stock is priced at $0.69, giving the company a market capitalization of 4.08M. It carries a P/E multiple of -0.02.

As of 2025-12-20, Salarius Pharmaceuticals(SLRX) stock has fluctuated between $0.66 and $0.72. The current price stands at $0.69, placing the stock +5.3% above today's low and -3.7% off the high.

Salarius Pharmaceuticals(SLRX) shares are trading with a volume of 225.36K, against a daily average of 344.66K.

During the past year, Salarius Pharmaceuticals(SLRX) stock moved between $0.64 at its lowest and $108.00 at its peak.

During the past year, Salarius Pharmaceuticals(SLRX) stock moved between $0.64 at its lowest and $108.00 at its peak.

SLRX News

TipRanks 1d
Salarius Pharmaceuticals Adjourns Annual Meeting Over Quorum Shortfall

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...

TipRanks 3d
Salarius announces planned corporate name change to Decoy Therapeutics

Salarius Pharmaceuticals (SLRX) announced that in connection with its recent combination with Decoy Therapeutics (DCOY), the Company intends to change its corpo...

People also own

Based on the portfolios of people who own SLRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.